Kristina Myhr‐Eriksson

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Bengt Simonsson, Tobias Gedde‐Dahl, Berit Markevärn et al. · Blood · 2011 · 194 citations · Full text

Medicine, Hematology, Oncology +10

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Martin Höglund, Fredrik Sandin, Karin Hellström et al. · Blood · 2013 · 127 citations

Medicine, Oncology, Pharmacotherapy +13

Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997–2013

Sören Lehmann, Stefan Deneberg, P Antunović et al. · Leukemia · 2017 · 63 citations

Medicine, Oncology, Cancer Epidemiology +11

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI

Johan Richter, Anna Lübking, Stina Söderlund et al. · Leukemia · 2021 · 27 citations · Full text

Medicine, Molecular Biology, Oncology +3

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Jani Huuhtanen, Mette Ilander, Bhagwan Yadav et al. · Journal of Clinical Investigation · 2022 · 22 citations · Full text

Medicine, Immunology, Oncology +17